Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 11;13(18):2910.
doi: 10.3390/diagnostics13182910.

IVDR: Analysis of the Social, Economic, and Practical Consequences of the Application of an Ordinance of the In Vitro Diagnostic Ordinance in Switzerland

Affiliations

IVDR: Analysis of the Social, Economic, and Practical Consequences of the Application of an Ordinance of the In Vitro Diagnostic Ordinance in Switzerland

Alix T Coste et al. Diagnostics (Basel). .

Abstract

IVDR regulation represents a major challenge for diagnostic microbiology laboratories. IVDR complicates a broad range of aspects and poses a risk given the high diversity of pathogens (including rare but highly virulent microbes) and the large variety of samples submitted for analysis. The regular emergence of new pathogens (including Echovirus E-11, Adenovirus 41, Monkeypox virus, Alongshan virus, and Enterovirus D68, as recent examples in Europe in the post SARS-CoV-2 era) is another factor that makes IVDR regulation risky, because its detrimental effect on production of in-house tests will negatively impact knowledge and expertise in the development of new diagnostic tests. Moreover, such regulations negatively impact the availability of diagnostic tests, especially for neglected pathogens, and has a detrimental effect on the overall costs of the tests. The increased regulatory burden of IVDR may thereby pose an important risk for public health. Taken together, it will have a negative impact on the financial balance of diagnostic microbiology laboratories (especially small ones). The already-high standards of quality management of all ISO-accredited and Swissmedic-authorized laboratories render IVDR law of little value, at least in Switzerland, while tremendously increasing the regulatory burden and associated costs. Eventually, patients will need to pay for diagnostic assays outside of the framework of their insurance in order to obtain a proper diagnostic assessment, which may result in social inequity. Thus, based on the risk assessment outlined above, the coordinated commission for clinical microbiology proposes adjusting the IvDO ordinance by (i) introducing an obligation to be ISO 15189 accredited and (ii) not implementing the IvDO 2028 milestone.

Keywords: IVDR; consequences; microbiology; risks.

PubMed Disclaimer

Conflict of interest statement

All authors are lab managers active in Switzerland and are impacted by the IvDO. G Greub has a research agreement with Becton-Dickinson on their BD Kiestra lab automated system and is medical advisor of Resistell, a start-up developing a new device for testing antibiotic susceptibility of bacteria. G Greub is also co-director of JeuPRO, a game company distributing games on microbes. A Egli is a medical advisor of two start-up companies, Sefunda and PhAST, both of which are developing rapid pathogen detection assays. However, no authors have a direct conflict of interest with the present position paper.

Figures

Figure 1
Figure 1
Notification and registration timelines. * Not necessary in Switzerland if already done in EU and authorized representative person domiciled in Switzerland.

Similar articles

Cited by

References

    1. European Union In vitro Diagnostic regulation. 2017. [(accessed on 1 July 2023)]. Available online: https://eur-lex.europa.eu/eli/reg/2017/746/oj.
    1. The Swiss Federal Council Ordinance on In Vitro Diagnostic Medical Devices (IvDO) 2022. [(accessed on 1 July 2023)]. Available online: https://www.fedlex.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2022/2....
    1. Kahles A., Goldschmid H., Volckmar A.L., Ploeger C., Kazdal D., Penzel R., Budczies J., Kempny G., Kazmierczak M. Structure and content of the EU-IVDR: Current status and implications for pathology. Pathologie. 2023:1–13. doi: 10.1007/s00292-022-01176-z. - DOI - PMC - PubMed
    1. Bank P.C.D., Jacobs L.H.J., van den Berg S.A.A., van Deutekom H.W.M., Hamann D., Molenkamp R., Ruivenkamp C.A.L., Swen J.J., Tops B.B.J., Wamelink M.M.C., et al. The end of the laboratory developed test as we know it? Recommendations from a national multidisciplinary taskforce of laboratory specialists on the interpretation of the IVDR and its complications. Clin. Chem. Lab. Med. 2020;59:491–497. doi: 10.1515/cclm-2020-1384. - DOI - PubMed
    1. van Deutekom H.W.M., Haitjema S. Recommendations for IVDR compliant in-house software development in clinical practice: A how-to paper with three use cases. Clin. Chem. Lab. Med. 2022;60:982–988. doi: 10.1515/cclm-2022-0278. - DOI - PubMed

LinkOut - more resources